Hepatitis C Lab Testing Comparison Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

1 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-07-24

Study Completion Date

2024-12-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hepatitis C (HCV) HCV antibody assays are the standard of care test used to screen for HCV, but confirmation of acute infection is relegated in the current US guidelines to polymerase chain reaction (PCR) which often takes multiple days and may result in a loss to follow up and treatment, especially in high prevalence populations. HCV core antigen is a new, research use only immunoassay intended for use on the Abbott Alinity i system, an FDA-cleared instrument for clinical chemistry and immunoassay testing. The aim of the study is to evaluate the 48-hour stability of HCV core antigen in fresh serum and plasma specimens collected from individuals with a detectable HCV viral load (HCL VL), as per a recent antibody assay test, under multiple specimen storage conditions mirroring those employed in clinical laboratories.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of OraQuick HCV Rapid Antibody Test and Standard Serologic Screening for Hepatitis C: Validity, Acceptability and Impact on Linkage to Care

NCT02084719

Active or Ex-injection Drug Users Indication of Hepatitis C Screening

TERMINATED NA

HCV Test and Treat Utilizing Simplified HCV Patient Education

NCT05582681

Hepatitis C

TERMINATED PHASE4

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

NCT00277238

Hepatitis, Chronic Active

COMPLETED PHASE2

Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)

NCT05016609

Hepatitis C

RECRUITING PHASE4

Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment

NCT00006164

Chronic Hepatitis c Cirrhosis, Liver Fibrosis, Liver +1 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study seeks to test the stability of a novel method of hepatitis-C testing called HCV core antigen testing. This will be accomplished by prospectively consenting patients who have had a recent, positive standard of care HCV viral load test, and drawing additional blood to conduct HCV core antigen testing within the infectious period. Viral load amount of the core antigen test will be recorded at baseline and subsequent timepoints. Stability is defined as \<10% change from baseline and will be recorded at various timepoints up to 144 hours post-draw. Stability will also be tested at room temperature vs. refrigerated storage and on the gel vs. off the gel processing techniques. This information is necessary to ensure HCV core antigen is sufficiently stable following specimen collection to enable robust, accurate, and precise measurement using the HCV core antigen assay.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

In vitro stability investigation

Hepatitis C core antigen

Intervention Type DIAGNOSTIC_TEST

Semi-quantitative, automated immunoassay detecting core antigen of hepatitis C virus.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hepatitis C core antigen

Semi-quantitative, automated immunoassay detecting core antigen of hepatitis C virus.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to provide informed consent
* Had detectable HCV VL in a standard of care Hepatitis C RNA Quantitative test
* Initial hepatitis C VL testing took place at any HealthPartners lab
* Able to undergo a study blood draw within 3 weeks of initial hepatitis C VL testing
* Ability to sign e-consent prior to presenting for a study lab draw